Abstract
Objective
The present study compared recent trends in benzodiazepine and antidepressant consumption in Italy and projected their global sales in the future. We investigated whether the increasing use of antidepressants is associated with a progressive reduction in benzodiazepine use.
Methods
Data concerning actual quantities of benzodiazepines and antidepressants dispensed in Italy from 1995 to June 2003 were obtained from IMS Health. For each agent, the number of defined daily doses (DDDs) per 1000 inhabitants per day and the annual expenditure in Euros was calculated.
Results
During the 9-year period, benzodiazepine consumption remained substantially stable, accounting for 50 DDDs/1000 per day in 2003. In the same period, antidepressant consumption dramatically rose, from 9 DDDs/1000 per day in 1995 to 26 DDDs/1000 per day in 2003, an increase of nearly three times. While the use of tricyclic antidepressants declined by one-third and that of other older agents remained substantially stable, the use of selective serotonin-reuptake inhibitors and newer agents (venlafaxine, mirtazapine, reboxetine) increased by 623%. Global consumption of antidepressants was projected to increase still further, and, in 2007, the total sales of antidepressants were projected to be similar to the total sales of benzodiazepines. The value of benzodiazepine sales increased from 322 million to 565 million Euros, an increase of 43%; similarly, the value of antidepressant sales increased from 186 million to 569 million Euros, an increase of 67%.
Conclusions
In Italy, the consumption of benzodiazepines was not affected by the increased prescribing of selective serotonin-reuptake inhibitors and newer antidepressants.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dimmock PW, Wyatt KM, Jones PW et al (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356:1131–1136
Isacsson G, Boethius G, Henriksson S et al (1999) Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. J Affect Disord 53:15–22
Lawrenson RA, Tyrer F, Newson RB et al (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59:149–157
Middleton N, Gunnell D, Whitley E et al (2001) Secular trends in antidepressant prescribing in the UK, 1975–1998. J Public Health Med 23:262–267
Piccinelli M, Pini S, Bellantuono C et al (1995) Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 166:424–452
Rosholm JU, Andersen M, Gram LF (2001) Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 56:923–929
Sramek JJ, Zarotsky V, Cutler NR (2002) Generalised anxiety disorder: treatment options. Drugs 62:1635–1648
Medawar C, Herxheimer A (2003) A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 16:5–19
Medawar C (1997) The antidepressant web—marketing depression and making medicines work. Int J Risk Saf Med 10:75–126
WHO Collaborating Centre for Drug Statistic Methodology (2003) Guidelines for ATC Classification and DDD Assignment. WHO Collaborating Centre for Drug Statistic Methodology, Oslo
Jones G (2003) Prescribing and taking medicines: concordance is a fine theory but it is mostly not being practised. BMJ 327: 819
Barbui C, Broglio E, Costa Laia A, D’Agostino S, Enrico F, Ferraro L, Fiorio E, Miletti F, Pietraru C, Poggio L, Tognoni G (2003) Cross-sectional database analysis of antidepressant prescribing in Italy. J Clin Psychopharmacol 23:31–34
Tiller JW (1994) Reducing the use of benzodiazepines in general practice. BMJ 309:3–4
Martikainer J, Paakkari P, Paldàn M, Voipo T (2002) Medicines in 2002. Laakevuosi 28:21–28
Busto U, Lanctot KL, Isaac P, Adrian M (1989) Benzodiazepine use and abuse in Canada. Can Med Ass J 141:917–921
Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D (1993) Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health 17:345–349
APA (American Psychiatric Association) (1990) Benzodiazepine dependency, toxicity, and abuse. Washington
O’Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K (1999) Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 48:980–990
Dubini A, Mannheimer R, Pancheri P (2001) Depression in the community: results of the first Italian survey. Int Clin Psychopharmacol 16:49–53
Bellantuono C, Mazzi MA, Rizzo R, Tansella M, Goldberg DP (2002) The identification of depression and the coverage of antidepressant drug prescriptions in Italian general practice. J Affect Disord 72:53–59
Rose N (2003) Neurochemical selves. Society November/December, pp 46–59
Acknowledgements
The authors have never received financial support from drug companies and have never done consultancy for pharmaceutical companies. This work received no funding. Arcangelo Ciuna suddenly died during the preparation of this manuscript, which is dedicated to his memory.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ciuna, A., Andretta, M., Corbari, L. et al. Are we going to increase the use of antidepressants up to that of benzodiazepines?. Eur J Clin Pharmacol 60, 629–634 (2004). https://doi.org/10.1007/s00228-004-0810-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0810-8